ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 158767" data-attributes="member: 13851"><p><span style="color: rgb(184, 49, 47)"><strong>Abstract </strong></span></p><p></p><p><strong>Background:</strong> <span style="color: rgb(26, 188, 156)"><strong>To compare the efficacies of gonadotropin-releasing hormone (GnRH) pulse subcutaneous infusion</strong></span> <span style="color: rgb(44, 130, 201)"><strong>with combined human chorionic gonadotropin and human menopausal gonadotropin (HCG/HMG) intramuscular injection have been performed to treat male hypogonadotropic hypogonadism (HH) spermatogenesis. </strong></span></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Methods:</strong></span> <span style="color: rgb(0, 0, 0)">In total, 220 idiopathic/isolated HH patients were divided into the GnRH pulse therapy and HCG/HMG combined treatment groups (n=103 and n=117, respectively). The luteinizing hormone and follicle-stimulating hormone levels were monitored in the groups for the 1st week and monthly, as were the serum total testosterone level, testicular volume and spermatogenesis rate in monthly follow-up sessions.</span></p><p></p><p><strong>Results:</strong> <span style="color: rgb(26, 188, 156)"><strong>In the GnRH group and HCG/HMG group, the testosterone level and testicular volume at the 6-month follow-up session were significantly higher than were those before treatment.</strong> </span>There were 62 patients (62/117, 52.99%) in the GnRH group and 26 patients in the HCG/HMG (26/103, 25.24%) group who produced sperm following treatment. <span style="color: rgb(26, 188, 156)"><strong>The GnRH group (6.2±3.8 months) had a shorter sperm initial time</strong></span> <span style="color: rgb(44, 130, 201)"><strong>than did the HCG/HMG group (10.9±3.5 months).</strong></span> <strong><span style="color: rgb(250, 197, 28)">The testosterone levels in the</span><span style="color: rgb(26, 188, 156)"> GnRH </span><span style="color: rgb(250, 197, 28)">and</span><span style="color: rgb(44, 130, 201)"> HCG/ HMG</span><span style="color: rgb(250, 197, 28)"> groups were </span><span style="color: rgb(26, 188, 156)">9.8±3.3 nmol/L</span><span style="color: rgb(250, 197, 28)"> and </span><span style="color: rgb(44, 130, 201)">14.8±8.8 nmol/L, </span><span style="color: rgb(250, 197, 28)">respectively. </span></strong></p><p></p><p><strong>Conclusion:</strong> <span style="color: rgb(26, 188, 156)"><strong>The GnRH pulse subcutaneous infusion successfully treated male patients with HH, leading to earlier sperm production </strong></span><span style="color: rgb(44, 130, 201)"><strong>than that in the HCG/HMG-treated patients.</strong></span> <span style="color: rgb(26, 188, 156)"><strong>GnRH pulse subcutaneous infusion is a preferred method. </strong></span></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">5.</span> Conclusion </strong></p><p></p><p><span style="color: rgb(26, 188, 156)"><strong>Our study suggested that GnRH pulse infusion therapy simulates the physiologic secretion of the human GnRH pulse, which is more consistent with the physiologic state.</strong></span><span style="color: rgb(44, 130, 201)"><strong> Compared with the combined treatment of HCG/HMG, </strong></span><strong><span style="color: rgb(250, 197, 28)">GnRH pulse subcutaneous infusion can promote spermatogenesis faster.</span></strong><span style="color: rgb(250, 197, 28)"> <strong>Therefore, GnRH pulse subcutaneous infusion is an optimal choice for the treatment of spermatogenesis in patients with HH. </strong></span></p></blockquote><p></p>
[QUOTE="madman, post: 158767, member: 13851"] [COLOR=rgb(184, 49, 47)][B]Abstract [/B][/COLOR] [B]Background:[/B] [COLOR=rgb(26, 188, 156)][B]To compare the efficacies of gonadotropin-releasing hormone (GnRH) pulse subcutaneous infusion[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]with combined human chorionic gonadotropin and human menopausal gonadotropin (HCG/HMG) intramuscular injection have been performed to treat male hypogonadotropic hypogonadism (HH) spermatogenesis. [/B][/COLOR] [COLOR=rgb(0, 0, 0)][B]Methods:[/B][/COLOR] [COLOR=rgb(0, 0, 0)]In total, 220 idiopathic/isolated HH patients were divided into the GnRH pulse therapy and HCG/HMG combined treatment groups (n=103 and n=117, respectively). The luteinizing hormone and follicle-stimulating hormone levels were monitored in the groups for the 1st week and monthly, as were the serum total testosterone level, testicular volume and spermatogenesis rate in monthly follow-up sessions.[/COLOR] [B]Results:[/B] [COLOR=rgb(26, 188, 156)][B]In the GnRH group and HCG/HMG group, the testosterone level and testicular volume at the 6-month follow-up session were significantly higher than were those before treatment.[/B] [/COLOR]There were 62 patients (62/117, 52.99%) in the GnRH group and 26 patients in the HCG/HMG (26/103, 25.24%) group who produced sperm following treatment. [COLOR=rgb(26, 188, 156)][B]The GnRH group (6.2±3.8 months) had a shorter sperm initial time[/B][/COLOR] [COLOR=rgb(44, 130, 201)][B]than did the HCG/HMG group (10.9±3.5 months).[/B][/COLOR] [B][COLOR=rgb(250, 197, 28)]The testosterone levels in the[/COLOR][COLOR=rgb(26, 188, 156)] GnRH [/COLOR][COLOR=rgb(250, 197, 28)]and[/COLOR][COLOR=rgb(44, 130, 201)] HCG/ HMG[/COLOR][COLOR=rgb(250, 197, 28)] groups were [/COLOR][COLOR=rgb(26, 188, 156)]9.8±3.3 nmol/L[/COLOR][COLOR=rgb(250, 197, 28)] and [/COLOR][COLOR=rgb(44, 130, 201)]14.8±8.8 nmol/L, [/COLOR][COLOR=rgb(250, 197, 28)]respectively. [/COLOR][/B] [B]Conclusion:[/B] [COLOR=rgb(26, 188, 156)][B]The GnRH pulse subcutaneous infusion successfully treated male patients with HH, leading to earlier sperm production [/B][/COLOR][COLOR=rgb(44, 130, 201)][B]than that in the HCG/HMG-treated patients.[/B][/COLOR] [COLOR=rgb(26, 188, 156)][B]GnRH pulse subcutaneous infusion is a preferred method. [/B][/COLOR] [B][COLOR=rgb(184, 49, 47)]5.[/COLOR] Conclusion [/B] [COLOR=rgb(26, 188, 156)][B]Our study suggested that GnRH pulse infusion therapy simulates the physiologic secretion of the human GnRH pulse, which is more consistent with the physiologic state.[/B][/COLOR][COLOR=rgb(44, 130, 201)][B] Compared with the combined treatment of HCG/HMG, [/B][/COLOR][B][COLOR=rgb(250, 197, 28)]GnRH pulse subcutaneous infusion can promote spermatogenesis faster.[/COLOR][/B][COLOR=rgb(250, 197, 28)] [B]Therefore, GnRH pulse subcutaneous infusion is an optimal choice for the treatment of spermatogenesis in patients with HH. [/B][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top